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Abstract
Purpose Comprehensive genomic profiling identifying actionable molecular alterations aims to enable personalized treatment 
for cancer patients. The purpose of this analysis was to retrospectively assess the impact of personalized recommendations 
made by a multidisciplinary tumor board (MTB) on the outcome of patients with breast or gynecological cancers, who had 
progressed under standard treatment. Here, first experiences of our Comprehensive Cancer Center Molecular Tumor Board 
are reported.
Methods All patients were part of a prospective local registry. 95 patients diagnosed with metastatic breast cancer or gyneco-
logical malignancies underwent extended molecular profiling. From May 2017 through March 2019, the MTB reviewed all 
clinical cases considering tumor profile and evaluated molecular alterations regarding further diagnostic and therapeutic 
recommendations.
Results 95 patients with metastatic breast or gynecological cancers were discussed in the MTB (68% breast cancer, 20% 
ovarian cancer, 5% cervical cancer, 3% endometrial cancer and 4% others). Genes with highest mutation rate were PIK3CA 
and ERBB2. Overall, 34 patients (36%) received a biomarker-based targeted therapy recommendation. Therapeutic recom-
mendations were implemented in nine cases; four patients experienced clinical benefit with a partial response or disease 
stabilization lasting over 4 months.
Conclusion In the setting of a multidisciplinary molecular tumor board, a small but clinically meaningful group of breast 
and gynecological cancer patients benefits from comprehensive genomic profiling. Broad and successful implementation 
of precision medicine is complicated by patient referral at late stage disease and limited access to targeted agents and early 
clinical trials.
Trial registration number 284-10 (03.05.2018).
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Introduction
In women, metastatic breast cancer and gynecological 
malignancies are among the most frequent causes of can-
cer death.  In 2018, there were an estimated 2,088,849 
new cases of breast cancer and 626,679 deaths, 569,847 
new cases of cervical cancer and 311 365 deaths, and 
295,414 new cases of ovarian cancer and 184,799 deaths 
worldwide. [1] Despite rising overall incidence, mortal-
ity rate has steadily decreased owing to early detection 
and improvements in the therapeutic management of 
these patients. However, although the development of new 
drugs, vaccines, and systematic screening programs has 
improved patients’ outcomes, effective measures to suc-
cessfully treat metastatic cancer are still missing.
With the advent of molecular diagnostics, cancer treat-
ment entered a new era. New techniques of sequencing 
DNA such as comprehensive genomic profiling (CGP) and 
hotspot next generation sequencing (NGS) provide tools 
for deciphering complete genes and later entire genomes 
at unprecedented speed [2]. These new approaches led to 
the development of a novel cancer treatment movement, 
known as precision medicine. By selecting the most effec-
tive treatment based on the molecular characteristics of 
tumor tissues or some other biologic parameters of the 
malignant disease, precision medicine aims to offer per-
sonalized treatment concepts to cancer patients with 
limited standard of care options. Molecular therapeutic 
agents (MTA) targeting individual actionable molecular 
alterations have been successfully developed in the past 
few years, showing the positive impact of using molecu-
lar-based therapy on the cancer patients’ outcome [3–6]. 
These include the use of growth factor receptor 2 antibody 
trastuzumab in breast cancer, a tyrosine kinase inhibitor 
imatinib in myelogenous leukemia associated with the 
BCR-ABL fusion gene and EGFR tyrosine kinase inhibi-
tors in lung carcinomas [7, 8].
Breast and gynecological cancers constitute a heteroge-
neous group of malignant diseases associated with multiple 
genetic alterations [9–11]. In the past few years, a growing 
number of molecular markers in breast cancer, for example, 
have been investigated and some of them are now well-estab-
lished as reliable predictors of prognosis and response to 
tumor therapy (Fig. 1a). Moreover, many different targeted 
therapies have been approved for use in breast cancer treat-
ment (Fig. 1b).  The recent approval of the PIK3CA specific 
inhibitor alpelisib has been the most recent example of tar-
geted agents moving into routine care. [12] Treatment with 
alpelisib was shown to prolong PFS by more than 6 months 
compared to the control arm. [13]
In gynecologic malignancies, MTAs have also been 
successfully implemented into clinical care. For example, 
early data from a clinical phase II trial focusing on BRCA-
mutated ovarian cancer showed that olaparib as mainte-
nance treatment significantly improved progression-free 
survival (PFS) in relapsed platinum-sensitive ovarian can-
cer [15]. In 2018, these data could be transferred to the 
first line setting when treatment effects of the SOLO1 trial 
were presented [16]. Due to an impressive PFS improve-
ment and a 70% lower risk of disease progression or death 
with olaparib compared to placebo, this effect led to the 
incorporation of PARP inhibitors into the primary treat-
ment of ovarian cancer in 2019 [17]. However, when it 
comes to other gynecologic malignancies such as endome-
trial cancer, the development of MTA is delayed in com-
parison to other malignancies.
By detecting potential actionable pathways using 
molecular diagnostics, it is also possible to assess and 
treat various cancer types. For example, the ERBB2/PIK3/
AKT/mTOR pathway is known for its relevance in breast 
cancer, but recently a relevant actionable mutation from 
the same pathway,  PIK3R1W624R was also identified in 
ovarian cancer [18].  Another study suggested that some 
subtypes of cervical cancers may also benefit from existing 
ERBB2/PIK3/AKT/mTOR targeted agents [19].
With the rising number of MTAs and considering the 
heterogeneous molecular profiles of breast cancer and 
gynecological malignancies, it is reasonable to expect 
that patients with these malignancies could potentially 
benefit from implementation of precision oncology based 
on comprehensive genomic profiling (CGP) into clinical 
care. Promising early data for such malignancies has been 
presented in multiple trials. In breast cancer, many reports 
of such driver alterations have emerged in the past few 
years, suggesting that patients could profit from preci-
sion medicine and targeted therapies [20]. For example, 
in the SAFIR01 multicenter prospective trial, data of pre-
cision medicine benefitting breast cancer patients were 
presented. 9 out of 43 patients (21%) responded to the 
recommended targeted therapy with a stable disease last-
ing over 16 weeks [21]. In ovarian cancer, multiplatform 
molecular profiling, conducted in a commercially available 
profiling center, led to a significantly longer post-profiling 
survival in patients, who were treated with profile-guided 
targeted agents, in comparison to the control group [22].
With the technical advances in molecular diagnostics 
and the continuous approval of many targeted therapies, 
the growing field of precision medicine is constantly 
expanding and requires optimization. Considering the 
complexity of precision medicine in oncology, it was 
reasonable to create a molecular tumor board (MTB) to 
leverage the knowledge of the many different disciplines 
involved in oncological treatment and to provide opti-
mal treatment recommendations. In this manuscript, first 
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experiences of the Comprehensive Cancer Center (CCC) 
LMU Munich Molecular Tumor Board are presented.
The aim of this project was to retrospectively measure the 
impact of MTB discussions and recommendations made by 
a multidisciplinary tumor board on outcome of patients with 
breast and gynecological cancers progressing under standard 
treatment. Detailed information including data on patient char-
acteristics, diagnostic and treatment recommendations, imple-
mentation of the recommendations, and outcome of treated 
patients with breast and gynecological cancers (ovarian, endo-
metrial, cervix, and other type of cancer) are presented.
Materials and methods
All patients reported here were discussed in the local MTB, 
which reviewed clinical cases and the respective tumor pro-
files with the associated actionable alterations. The final 
result of each MTB case discussion was a report, focused 
on NGS data and diagnostic and potential diagnostic, and 
therapeutic alternatives. Thereby, the MTB presented itself 
as a multidisciplinary team (MDT), which comprised 
clinical oncologists, pathologists, molecular pathologists, 
genetic counselors, bioinformaticians, and scientists with 
expertise in genetic and tumor profiling in diverse cancers. 
MTB-meetings were held every 2 weeks with the purpose 
of interpretation and/or translation of the molecular diag-
nostics’ results into diagnostic and/or treatment recommen-
dations. All patients’ cases were first presented at organ-
specific gynecology tumor boards by a team of experienced 
gyneco-oncologists, who reviewed all the clinical course of 
every individual patient and discussed if patients were eli-
gible for a MTB discussion. Apart from recent tumor mate-
rial, recent radiology images and other diagnostic tests were 
also required for the interdisciplinary setting of the MTB. 
All treatment recommendations were supported by levels of 
Fig. 1  Predictive factors (a) and 
treatment-relevant genetic alter-
ations (b) in metastatic breast 
cancer, German Gynecologi-
cal Oncology Group. In 2018, 
AGO was the first international 
guideline-commission to make 
recommendations regarding 
precision medicine in breast 
cancer. (http://www.ago-onlin 
e.de) [14]
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evidence by using the ESMO Scale for Clinical Actionability 
of molecular Targets (ESCAT). The process from enrolling 
the patient into the study till receiving a recommendation by 
the MTB is shown in Fig. 2.
Patients and patient informed consent
All patients discussed (n = 95) were included in the prospec-
tive single-center case study, “The informative Patient”, 
launched in March 2017 at the LMU University Hospital, 
Munich as a Munich-site part of the DKTK (German Cancer 
Consortium) program. All enrolled patients suffered from 
metastatic breast or gynecological cancer which had pro-
gressed after at least one line of prior standard treatment 
and who had no longer access to curative treatment. Prior 
to inclusion, all participants signed an informed consent 
that they were informed about potential and limitations that 
molecular diagnostics could offer for treatment selection 
and for analysis of their data, further discussion of their 
case by a multidisciplinary MTB, as well as for collecting 
follow-up data on the course of disease for research purpose 
(including requesting patient data from other physicians and 
institutions).
The intention-to-treat (ITT) population consisted of 100 
patients. Eventually, five patients were excluded, because of 
death prior to a treatment recommendation or withdrawal 
of consent.
The data here are based on the results of an ITT popula-
tion of 95 patients.
Molecular pathology
Molecular analyses were performed at the Institute of 
Pathology of the LMU. Appropriate tissue regions were 
selected histo-morphologically from formalin-fixed paraf-
fin embedded (FFPE)- or fresh frozen tissue. Moreover, 
liquid biopsies (blood, liquor) were included. In only four 
patients, analysis had to be repeated due to material con-
straints. Targeted NGS was performed with the Oncomine 
Comprehensive Cancer v.3 Panels (Agilent) thereby screen-
ing for changes in 161 genes on DNA (SNV, MNV, small 
ins, del, indels, CNV) and RNA (gene fusions) level. DNA 
and RNA were isolated using Qiagen’s GeneRead DNA 
FFPE- or RNeasy FFPE-kits, respectively. Nucleic acids 
(NA; DNA, and RNA) from liquid biopsies were prepared 
by utilization of the QIAamp Circulating Nucleic Acid Kit. 
Subsequently, library preparation as first step of NGS was 
generated by employing Ampliseq Library Plus-, Ampliseq 
cDNA synthesis-, Ampliseq CD index, Ampliseq Equal-
izer- together with Ampliseq Comprehensive v3-kits (all 
Illumina) or DNA- and RNA-Oncomine Comprehensive 
Panels v3 and Ion AmpliSeq Library-, IonXpress Barcode 
Adapter-, Ion Library Equalizer-kits together with Ion Chip 
kits (mostly 550) (all Thermo Fisher), following for each 
step the respective user manuals. Libraries were run on 
an Ion Torrent GeneStudio S5 Primer (Thermo Fisher) or 
Illumina 500 Next Seq (Illumina) NGS machine. Analysis 
of results was performed with either the Ion-Reporter Sys-
tem (Thermo Fisher) followed by further variant and qual-
ity interpretation with a self-made excel tool or annotating 
Fig. 2  MTB, from suggestion to conclusion
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VCF-files using wAnnovar (http://wanno var.wglab .org/) [23] 
together with the self-made python-script PathoMine filter-
ing for clinically relevant mutations. Mutations were judged 
as relevant on the basis of the key ’interpretation’ given in 
ClinVar [24]. Alterations were confirmed with the Inte-
grated Genomics Viewer (IGV, Broad Institute). The result-
ing molecular pathological dataset together with data from 
immunohistochemistry, fluorescence in situ hybridization 
(FISH), and histo-morphology became part of a compre-
hensive pathological report which was sent out to the MTB.
Data assessment
For this analysis, electronic medical records were reviewed 
for patient characteristics and follow-up. If needed, medical 
oncologists, gynecologists, and general practitioners were 
contacted in order to collect follow-up data on treatment 
course and patient status. Patient characteristics were sum-
marized using descriptive statistics. Follow-up of clinical 
outcomes was performed to track tumor response to recom-
mended therapies and analyzed by measuring progression-
free survival (PFS) of patients, who received the recom-
mended treatment. PFS was calculated from the first day of 
treatment with the recommended in- or off-label targeted 
drug until the date of disease progression or death, which-
ever occurred first, analogous to the Johns Hopkins MTB 
study and to the Von Hoff et al. study [25]. In order to evalu-
ate the benefit of the treatment recommendation, we then 
calculated the PFS ratio (PFSr) by comparing the PFS of 
the recommended treatment and the PFS of the previous 




From March 2017 through March 2019, a total of 95 cases 
were submitted to the MTB. All patients (n = 95) were 
females, had an underlying malignant condition, suffered 
from metastatic disease, and had experienced disease pro-
gression under standard treatment. Patients with imple-
mented therapy recommendations had received a median 
of five (range 2–6) prior therapies for metastatic cancer. 
The median age at time of the initial MTB presentation was 
52 years (range 19–82 years).
As shown in Fig. 3, the most frequent tumor type was 
breast cancer (n = 64, 68%), followed by ovarian cancer 
(n = 19, 20%). The majority of patients with breast cancer 
had triple-negative (ER, PR and HER2 negative; n = 30; 
46.9%), followed by estrogen receptor (ER) -positive and/
or progesterone receptor (PR) -positive, human epidermal 
growth factor receptor 2 (HER2) -negative (luminal-like) 
(n = 28; 43.8%), or HER2 positive, ER-negative, PR-negative 
disease (n = 5; 7.8%) at the time of the MTB case discussion; 
Fig. 3  Distribution of the cases 
discussed at the MTB meeting 
by tumor entity (n = 95)
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one patient (1.6%) had triple-positive disease (ER positive 
and/or PR positive, HER2 positive).
Characteristics of patients with a molecular profile are 
reported in Table 1.
Molecular profiling
Molecular tests using NGS were performed for all 95 
patients. Out of the set of mutations from the molecular 
pathological NGS-analysis, actionable mutations were 
defined as those matching or informing the use of avail-
able targeted agents.
Four patients had tumor sequencing performed twice 
during the course of disease. 81 (85.3%) patients had suit-
able tissues for multimodal molecular profiling (NGS). 
All in all, 103 molecular alterations were identified in 
55 cases (57.9%). The median number of alterations 
observed in each sample was one (range 0–6). Out of 
the 55 patients, 41 (43.2%) had an actionable mutation, 
which the board reviewed as a potentially targetable. No 
genomic alterations in the 161 investigated genes were 
found in 40 (42.1%) analyses, in 14 (14.7%) of which the 
molecular diagnostics test was technically not success-
ful because of poor DNA quality or insufficient material 
quality. Although five (5.3%) patients had an actionable 
mutation, they did not receive a therapy recommendation 
because of co-morbidities, not meeting trial inclusion cri-
teria, or other requirements for receiving a specific tar-
geted therapy.
We discovered mutations in over 30 different genes. 
Among the patients tested, the most common altera-
tions were as follows: PIK3CA mutation (13/95; 13.7%); 
ERBB2 mutation (10/95; 10.5%); KRAS mutation (9/95; 
9.5%), and CCND1 mutation (9/95; 9.5%). Incidences of 
Table 1  Patient characteristics
Covariables
Median age at diagnosis 47 years (range 12–80)
Age at diagnosis





 ≥ 70 4 (4.2%)
Median age at MTB case presentation 52 years (range 19–82)
 Age at MTB case presentation





 ≥ 70 8 (8.4%)
Fig. 4  Frequency of genomic alterations for the different tumor entities (n = 95)
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genomic alterations by gene and the distribution of molec-
ular alterations by tumor type are shown in Fig. 4.
Recommendations
Among the 55 (57.9%) patients with at least one molecular 
alteration identified, 41 patients (43.2%) had an actionable 
alteration, whereas 14 (14.7%) had only non-actionable 
variants. Eventually, this resulted in 15 diagnostic and 49 
treatment recommendations for 45 patients (47.4%). Multi-
ple recommendations were adjusted for 20 (21.1%) patients 
(multiple recommendation principle). Six patients received 
a conditional recommendation, which required specific 
further diagnostics, two of which resulted in a treatment 
recommendation.
Diagnostic recommendations
Out of 15 diagnostic recommendations, 10 were pursued. In 
seven (7.4%) cases, extended genetic analyses were recom-
mended and eventually six (6.3%) of them were performed. 
Re-biopsies were recommended in 14 cases, when the initial 
diagnostic tests were technically not successful, which we 
did not include in the evaluation of the final results.
Therapeutic recommendations
As shown in Fig. 5, 36 (37.9%) patients were given a ther-
apy recommendation, 14 (14.7%) of whom received more 
than one treatment suggestion, as their tumor molecular 
profile revealed more than one actionable mutation. Two 
(2.1%) patients were excluded from the evaluation of the 
clinical outcome, as they received the recommended therapy 
in the period between NGS analysis and MTB treatment 
recommendation.
Overall, 9 of 34 therapeutic recommendations were 
pursued. Of note, in the present cohort, no patient pursued 
the recommended enrollment in a clinical trial. In-label 
therapy recommendations were implemented in five cases, 
whereas off-label recommendations were implemented in 
four patients. The most common reasons for non-adminis-
tration of MTB-recommended therapy were deterioration 
of patients’ physical health condition, early death, no access 
to the recommended drug therapy, declined reimbursement 
applications by payer, or patient decision (see Table 2).
Clinical outcome
All patients were included in the registry after multiple 
standard of care treatments.
Out of nine (9.5%) patients following therapy recom-
mendation, 4 (4.2%) showed a state of partial remission or 
stabilization lasting more than 16 weeks, including two of 
them receiving off-label therapy recommendation. Compar-
ing PFS of the recommended therapy with the PFS of the 
previously received systemic treatment, we estimated that 
four of nine responders receiving MTB-recommended thera-
pies displayed a progression-free survival (PFS) ratio (PFS2/
PFS1; PFSr) > 1.3, showing the relevance of the suggested 
therapies. Two patients responded with an ongoing PFSr. 
Figure 6 details the actual comparison of PFS on imple-
mented recommended treatment versus PFS on the patient’s 
last prior treatment.
More information about the outcome of responding 
patients is shown in Table 3.
See Appendix for details of identified actionable muta-
tions and corresponded treatment recommendations made 
by the MTB.
Discussion
We evaluated the clinical consequences of actionable genetic 
alterations (by NGS) in 95 patients with metastatic breast 
cancer and gynecological malignancies, part of a pilot 
monocentric patient registry with the purpose of generat-
ing real-world data. Forty-one patients (43.2%) had at least 
one actionable molecular aberration. The total number of 
patients with a drug-targetable alteration was 34 (35.7%). 
Overall, 9 of 34 patients (9.5% of all) received the recom-
mended drug treatment. In a small, but significant group 
of patients, four out of nine with implemented therapy 
recommendations (44.4%) experienced a clinical benefit 
(PFSr > 1.3) lasting over 16 months, a result similar to the 
one shown by Jameson et al. in cases of patients with meta-
static breast cancer, who received personalized therapy rec-
ommendations based on multi-omic molecular profiling [26, 
27].
Precision medicine offers not only personalized treatment 
concepts for patients, but also helps us optimize diagnostic 
and treatment options by identifying biomarkers that are 
linked to response and resistance to immunotherapy. For 
instance, in the past few years, the problem of resistance to 
endocrine therapy has been a point of research. Recently, 
the key role of the acquisition of ligand-independent ESR1 
mutation in breast cancer as a common mechanism of resist-
ance to hormonal therapy was discovered [28].
So far, the precision medicine movement is controver-
sial and has sparked multiple debates. On the one hand, 
the SHIVA trial (2015), one of the first randomized inves-
tigation of precision therapy, was negative for its primary 
endpoint (progression-free survival [PFS]), as no statisti-
cally significant difference in PFS between patients receiv-
ing molecularly targeted agents and the control arm was 
demonstrated [29]. On the other hand, studies recruiting 
large number of patients, such as MOSCATO 01 (2017) 
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and ProfiLER (2017), suggested that high-throughput 
genomic analyses (i.e. next-generation sequencing, com-
prehensive genomic profiling) improve clinical outcome 
in patients with advanced cancers. However, this approach 
has only been proven to be beneficial to a small subset 
of patients so far [30, 31]. As shown in Table 4, studies 
focusing on precision medicine show different, contradic-
tory results. While in some studies more than 20% of the 
enrolled patients received the recommended according 
to molecular profiling treatment, in others the number of 
patients treated remains very low. These results suggest 
the need for large data collections in order to improve 
selection criteria and identify markers that discriminate 
patients that might benefit most from precision medicine.
Although molecular targeted agents themselves are more 
precise than standard cytotoxic agents, clinical evidence for 
a significant better outcome associated with MTAs is still 
missing, as the access to targeted therapies remains limited, 
Fig. 5  Treatment or diagnostic recommendations. Note, all numbers 
do not add up because some patients are counted in more than one 
category (e.g., had an actionable alteration for a treatment recommen-
dation and also for diagnostic recommendation or received more than 
one treatment/ diagnostic recommendation). a Diagram representing 
the outcome of the molecular diagnostic testing (n = 95). b Breast 
cancer patients. c Gynecological cancer patients
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making collecting data regarding their efficacy difficult. In 
order to achieve their implementation in clinical care, a re-
assessment of the standards of evidence sufficient to prove 
the benefit of precision cancer therapies is needed [32]. New 
evidence suggests that appropriately conducted real-world 
data studies have the potential to support regulatory deci-
sions in the absence of RCT data [33].
Based on initial results of the CCC LMU Munich, patients 
of various tumor entities benefit from extended molecular 
diagnostics and their implementation in clinical care [34]. 
Recently, many studies have described the positive effect 
of MTB case discussions for particular groups of patients 
with advanced solid cancers. However, there is not enough 
evidence for the utility of MTB decisions for patients with 
breast and gynecological malignancies.
The world of precision medicine is constantly evolv-
ing, and new targeted therapies are being developed and 
approved, enabling more and more patients (with up to this 
point of time not actionable mutation) to receive targeted 
therapies. For example, in spring 2019, the Food and Drug 
Administration of the USA (FDA) approved the PIK3CA 
inhibitor alpelisib in combination with endocrine therapy 
for patients with HR-positive, HER2-negative, PIK3CA-
mutated, advanced or metastatic breast cancer. The avail-
ability of this drug after start of the Managed Access Pro-
gram in our clinic could have resulted in five further therapy 
recommendations in our MTB cohort, showing the need of 
identifying such alterations in cancer patients.
Table 2  Recommendations (Note, some patients received more than 
one diagnostic and/or treatment recommendation.)
BC GC
Patients with min. 1 recommendation No No
  Diagnostic 8 7
 Therapeutic 27 7
 No treatment recommendation 30 20
 Conditional recommendation 3 3
 Referral to organ board 1
Diagnostic recommendations








 Targeted therapy 32 5
 Trial inclusion 8 2
 Checkpoint inhibition 1 1
Patients with treatment recommendations (n = 36)
 Implemented 7 1
 Non-implemented 22 6
Fig. 6  Comparison of PFS of previous line of therapy (PFS1) and implemented therapy recommendation (PFS2). PFS the period of time 
between the start of treatment till disease progression/ death
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Table 3  PFS ratio (PFSr) = ratio 
of patients’ PFS on the 
implemented recommended 
therapy (PFS2) (in this case the 
recommended in- or off-label 
targeted drug) to their PFS on 
the most recent previous line 
of therapy (standard of care) 
(PFS1)
PFSr PFS2/PFS1
# Tumor entity Treatment Label PFS2 (weeks) PFS1 (weeks) PFSr
1 Breast Everolimus In 14 81 0.17
2 Breast Everolimus In 12 55 0.22
3 Breast Exemestan + Everoli-
mus + Trastuzumab
Off 4 8 0.50
4 Breast Everolimus In 13 13 1.00
5 Breast Pazopanib Off 12 6 2.00
6 Breast Lapatinib In 18 3 6.00
7 Breast Palbociclib In 21 13 1.62
8 Breast Pembrolizumab Off 59 5 11.80
9 Cervix Temsirolimus Off 32 38 0.84
Table 4  Overview of studies focusing on molecular profiling
MP molecular profiled, PFS progression-free survival, ORR overall response rate, SD stable disease, PR disease progression, n.a.  not available
Author/Study Tumor entity Enrolled 
patients 
(n )
MP patients Actionable alterations Implemented 
therapies—n (% of 
enrolled)
Results
Le Tourneau et al. 
(SHIVA) [29]
Solid tumors 741 496 (67%) 293 (40%) 96 (13%) No significant difference 
in PFS (PFS: 2.3 vs 2.0 
p = .41), hazard ratio 
for death or disease 




Solid tumors 1893 1640 (87%) 187 (10%) 84 (5%) ORR: 19% in genotype-
matched group vs 9% 




Solid tumors 1035 843 (81%) 411 (40%) 199 (24%) ORR: 11%, SD 52%, 
PFSr > 1.3: 63/193 (33% 
of all treated patients 
or 7% of all enrolled 
patients)
Trédan et al. (PROFILER) 
[31]
Solid tumors 2579 1980 (77%) 1032 (40%) 163 (6%) ORR: 0.9% of all patients
Rodon et al. (WINTHER) 
[46]
Solid tumors 303 303 (100%) 25 (89%) 107 (35%) PFSr > 1.5: 22% of the 
patients with MP-based 
treatment
Hoefflin et al. [47] Solid tumors 198 n.a 104 (53%) 33 (17%) PR: 11/33 (33.3% of all 
treated patients or 5.5% 
of all enrolled patients)
SD: 8/33 (24.2% of all 




Breast cancer 423 299 (71%) 195 (46%) 55 (13%) ORR:4 patients had a 
partial response and 9 
had SD > 16 weeks (3% 
of all patients)
Parker et al. [27] Breast cancer 43 43 (100%) 40 (93%) 17 (40%) 7 patients (41% of all 
treated patients or 16% 
of all enrolled patients) 
achieved SD or PR
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The rising number of active targetable mutations affects 
the complexity of the results, making their interpretation a 
challenge for many oncologists. In 2014, Gray et al. con-
ducted a study, which evaluated cancer physicians’ ability 
of using multiplex tumor genomic testing and showed that 
many physicians lack confidence in interpreting complex 
genomic test results as well as in incorporating them into 
practice [35]. Thus, we see great potential in establishing the 
combination of molecular diagnostic tests and a subsequent 
case discussion by a multidisciplinary molecular board team 
not only as a routine for cancer patients but also as a training 
platform and a knowledge-expanding approach for oncolo-
gists to help guide their decisions.
However, precision oncology faces some challenges, 
which delay its widespread translation into clinical practice. 
Critics of the incorporation of NGS and similar methods into 
clinical practice express following concerns:
First, the significant cost of molecular diagnostics and 
targeted drugs is still a great disadvantage. While prices of 
next-generation sequencing technologies are dropping from 
about $3 billion in the year 2000 and to $5000 today, the 
selection of molecular targeted agents is still enormously 
expensive [36]. As the price of precision medicine is still 
rather high for most patients, it is now crucial to also evalu-
ate its cost-effectiveness in order to support its translation 
into clinical practice, for example in the setting of clinical 
trials and research programs [37].
Second, logistical problems causing limited access to 
targeted drugs and clinical trials for biomarker-positive 
patients represent another major problem. This is mainly 
due to the absence of reimbursement for drugs beyond their 
labelled indication. As a consequence, in order to receive the 
required, often off-label drug, patients need to be enrolled 
within active clinical trials or are required to cover the costs 
themselves or to file an application for reimbursement by 
the competent health insurance prior to treatment initiation. 
Clinical trials often have strict inclusion criteria and are, 
therefore, not easily accessible to many patients. As shown 
in the SAFIR01 trial, only a small number of patients ben-
efit from personalized therapies mostly due to drug access 
problems. This problem could be solved by establishing a 
portfolio of early phase clinical basket trials or by early-
access-programs [38]. Recent studies suggest that the imple-
mentation of a MTB improves access to targeted therapy 
[39]. As seen in our clinic, the early-access-program that 
we started in November 2019 enabled many patients with a 
PIK3CA mutation to derive benefit from the targeted drug 
alpelisib soon after its FDA approval in spring 2019 [40].
Third, another major limitation is the testing of tumors 
from patients with late stage disease, which limits treat-
ment options and hinders patients from receiving the rec-
ommended therapy or from enrolling in a clinical trial. As 
patients in an advanced cancer situation are often in an 
unstable health condition, obtaining biopsy material with 
a good quality of tissue is quite difficult. Our study had 14 
(14.7%) technically unsuccessful molecular diagnostics. 
Moreover, the time between enrolling patients in the study, 
processing tumor samples, followed by the molecular diag-
nostics and the MTB case discussion is still rather lengthy 
in view of the fact that malignancies in late stages tend to 
evolve at unprecedented speed, while causing deteriora-
tion of the general condition and hindering patients from 
receiving particular therapies, one of the main reasons for 
the relative low number of implemented therapies (9 out 
of 34). In this study, molecular profiling and discussion 
were completed in a clinically reasonable time frame of 
approximately 4 weeks, which is comparable to the median 
turnaround times in other studies. Therefore, it is reason-
able to expect that introducing molecular profiling at an 
earlier time point in a patient’s disease trajectory could 
improve the quality of molecular diagnostics and allow 
patients to benefit more from a multidisciplinary tailored 
MTB-based treatment advice.
Fourth, another concern is that the current trend of 
identifying single variables and matching it with an appro-
priate targeted therapy may be irrelevant for some patients 
because of the heterogeneous landscape of their cancer. 
Disease variability among individual tumors causes 
patients with tumors of similar histology to respond dif-
ferently to targeted therapies [41–43]. For example, only 
60% of lung cancer patients with the p.L858R mutation in 
the epidermal growth factor receptor gene (EGFR) respond 
to gefitinib, although all of them are carriers of the exact 
same mutation in the target gene, indicating that other, yet 
unknown genetic aberrations may influence the effect of 
targeted drugs and that the disease course is still unpre-
dictable to a great extent [44].
Fifth, the common use of medicines outside the 
approved label is controversial. Off-label drug use may 
represent a danger for patient safety in some cases, but 
it is sometimes justified from a clinical point of view. 
Four out of nine (44%) of the implemented recommended 
therapies in the study “The informative Patient” included 
off-label drugs; two of these patients (50%) experienced 
a clinical benefit with a partial response or stabilization 
lasting over 4 months, while having progressed under last 
standard treatment.
There were several limitations to our study. First, 
despite a relatively high number of breast and gynecologi-
cal cancer, the overall number of included patients remains 
low. Second, our patient cohort presented had a heteroge-
neous tumor type, making general conclusions relatively 
difficult. Third, the number of patients with implemented 
therapies is limited, due to deterioration of patients’ gen-
eral condition or no access to the recommended targeted 
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drug, as previously reported in other studies. Nevertheless, 
we do demonstrate feasibility of and patient benefit from 
a routine MTB at a large comprehensive cancer center.
Conclusion
The landscape of molecular alterations in breast and gyneco-
logical cancers is heterogeneous. Advances in the quality 
and availability of molecular diagnostics and the number 
of targeted therapies increase rapidly, offering patients with 
advanced cancer a variety of new treatment options. MTBs 
try to bridge the gap in between molecular alterations and 
matching drugs in a structured manner.
The primary objective of the present monocentric study 
was to estimate, in a real-world setting, the impact of inter-
disciplinary MTB case discussions for patients with breast 
and gynecological malignancies. Altogether, on the basis of 
individual molecular diagnostics, diagnostic and treatment rec-
ommendations were made for 45 patients (47.4% of all). Nine 
out of 34 patients received the recommended treatment. Four 
out of 9 patients responded with a PFSr > 1.3. Therefore, our 
results support the approach of matching specific drugs (in- and 
off-label) to particular genetic aberrations and demonstrate its 
relevance in breast and gynecological cancers for a small, but 
clinically relevant group of patients. By providing a multidisci-
plinary tailored-based treatment advice based on genetic tests, it 
is now possible for more patients with breast and gynecological 
malignancies to gain maximum clinical benefit and improve 
survival of patients with either advanced stage cancer or a rare 
tumor entity by applying personalized medicine.
The MTB strategy, however, needs to be standardized and 
optimized in order to eliminate major logistical problems 
such as limited access to targeted agents (often off-label) and 
clinical trials, as well as patient referral at stage disease that 
are too late for a beneficial therapeutic intervention.
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Table 5  Data supplement
# Mutation Tumor entity Treatment recommended in MTB Followed treatment / Line of 
therapy
PFS (months) 
after start of 
treatment
1 FGFR1, androgen receptor and 
CCND1 amplifications
Breast 1. CDK4/6 Inhibitor
2. Everolimus 3. androgen recep-
tor blocker
2 CCND1 amplification Breast 1. CDK4/6 Inhibitor
2. Palbociclib + Fulvestrant
3. Everolimus
Palbociclib 21
3 ERBB2 mutation Breast Afatinib / Neratinib
4 PTEN deletion; MET mutation Breast 1. NCT03337724 trial 2. Exemes-
tan + Everolimus
5 PIK3CA mutation Breast Everolimus
6 MET Exon 14 mutation Breast Crizotinib
7 MYC, FGFR1 and CCND1 
amplifications
Breast Everolimus Everolimus 13
8 androgen receptor amplification Breast 1. NCT01945775 / 
NCT02163694 trial
2. Bicalutamide / Tamoxifen
9 PIK3CA mutation Breast 1. SOLAR-1 / IPATunity130 trial 
2. Everolimus
10 ERBB2 amplification Breast Lapatinib, Trastuzumab, Emtan-
sine and Pertuzumab
11 ARID1A and PIK3CA mutations, 
LMB (4,16 muts/MB)
Breast Everolimus Everolimus 12
12 ESR1 mutation, CCND1 ampli-
fication
Breast Fulvestrant + 
Everolimus
13 TP53 and NOTCH1 mutations Breast Cyclophosphamid
14 TPM3(7)—NTRK1(10) gene 
fusion
Breast NCT02568267 trial
15 MET Exon 2 mutation Breast Cabozantinib
16 KRAS and 2 PIK3CA mutations Breast lipos. Doxorubicin / Beva-
cizumab + Temsirolimus/ 
Everolimus
17 androgen receptor mutation, 
PIK3CA mutation
Breast Everolimus
18 FGFR1, CCND1, EGFR, 
PIK3CA and PDGFRA ampli-
fications
Breast Pazopanib
19 ESR1 and PIK3CA mutations Breast 1. NCT03056755 trial
2. Everolimus
20 p16 high expression and MYC 
mutation
Breast Checkpoint inhibitor Pembrolizumab 59
21 androgen receptor amplification Breast Androgen receptor blocker
22 AKT mutation Breast 1. AKT inhibitors
2. IPATunity130 trial
3. Everolimus
23 SLX4 and TP53 mutations; 
amplifications: FGFR1, 
CCND1, FGF19, FGFR3
Breast Pazopanib Pazopanib 12
24 ESR1 mutation Breast Fulvestrant + 
CDK4/6 Inhibitoren
25 CCND1 and FGFR1 amplifica-
tions
Breast 1. Everolimus + antihormonal 
therapy;
2. Dovitinib
26 PIK3CA and ERBB2 mutations, 
high expression ERBB2
Breast 1. Pertuzumab/ Trastuzumab 
(+ Everolimus) 2. Neratinib
Lapatinib 18
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